Protalix BioTherapeutics (PLX) Work In Process (2012 - 2026)

Protalix BioTherapeutics has reported Work In Process for 9 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process rose 13.51% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $9.1 million (up 13.51% YoY), and the FY2025 full-year result was $9.4 million, down 16.63% from the prior year.
• Work In Process for Q1 2026 stood at $9.1 million, down from $9.4 million in the prior quarter.
• The five-year high for Work In Process was $12.3 million in Q3 2024, with the low at $1.5 million in Q1 2023.
• Average Work In Process over 5 years is $7.0 million, with a median of $8.1 million recorded in 2025.
• Year-over-year, Work In Process soared 498.11% in 2024 and sank 56.29% in 2025.
• Tracing PLX's Work In Process over 5 years: stood at $2.7 million in 2022, then soared by 238.13% to $9.1 million in 2023, then increased by 24.19% to $11.2 million in 2024, then fell by 16.63% to $9.4 million in 2025, then fell by 3.11% to $9.1 million in 2026.
• The last three Work In Process figures came in at $9.1 million (Q1 2026), $9.4 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.

Peer Comparison